External beam radiation therapy does not offer long-term control of prostate cancer

Urologic Clinics of North America

Volumn 23, Issue 4, 1996, Pages 617-621

  Goluboff, E T ^a   Benson, M C ^a  

^a Department of Orthopaedic Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BEAM THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME;

EID: 0030480404     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70340-2     Document Type: Article

References (31)

1. J. Adolfsson G. Steineck W.F. Whitmore Recent results of management of palpable clinically localized prostate cancer Cancer 72 1993 310
2. W.J. Catalona D.S. Smith 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer J Urol 152 1994 1837
3. W.J. Catalona D.S. Smith T.L. Ratliff J.W. Basler Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening JAMA 270 1993 948
4. A.V. D'amico R. Whittington S.B. Malkowicz A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer J Urol 154 1995 131
5. J. Fijuth B. Chauvet P. Vincent Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy Radiother Oncol 23 1992 236
6. J.D. Forman T. Oppenheim H. Liu Frequency of residual neoplasm in the prostate following threedimensional conformal radiotherapy Prostate 23 1993 235
7. H.A. Frazier J.E. Robertson P.A. Humphrey D.F. Paulson Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol 149 1993 516
8. J.R. Goad Chang S.-J. M. Ohori P.T. Scardino PSA after definitive radiotherapy for clinically localized prostate cancer Urol Clin North Am 20 1993 727
9. S.L. Hancock R.S. Cox M.A. Bagshaw Prostate-specific antigen after radiotherapy for prostate cancer: A reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University J Urol 154 1995 1412
10. G.E. Hanks A. Hanlon T. Schiltheiss Early prostate cancer: The national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group Studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation J Urol 152 1994 1775
11. G.E. Hanks W.R. Lee T.E. Schultheiss Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation J Urol 154 1995 456
12. J.N. Kabalin K.K. Hodge J.E. McNeal Identification of residual cancer in the prostate following radiation therapy: Role of transrectal ultrasound guided biopsy and prostate specific antigen J Urol 142 1989 326
13. D.A. Kuban A.M. El-Mahdi P.F. Schellhammer Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer Int J Radiat Oncol Biol Phys 32 1995 307
14. W.R. Lee G.E. Hanks T.E. Schultheiss Localized prostate cancer treated by external-beam radiotherapy alone: Serum prostate-specific antigen-driven outcome analysis J Clin Oncol 13 1995 464
15. A.W. Partin C.R. Pound J.Q. Clemens Serum PSA after anatomic radical prostatectomy Urol Clin North Am 20 1993 713
16. D.F. Paulson Impact of radical prostatectomy in the management of clinically localized disease J Urol 152 1994 1826
17. D.F. Paulson G.H. Lin W. Hinshaw S. Stephani Radical surgery versus radiotherapy for adenocarcinoma of the prostate J Urol 128 1982 502
18. T.M. Pisansky S.S. Cha J.D. Earle Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer J Clin Oncol 11 1993 2158
19. P.F. Schellhammer A.M. El-Mahdi G.L. Wright Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of the prostate Urology 42 1993 13
20. T.A. Stamey M.K. Ferrari Schmid H.-P. The value of serial prostate-specific antigen determination 5 years after radiotherapy: Steeply increasing values characterize 80% of patients J Urol 150 1993 1856
21. T.A. Stamey J.N. Kabalin M. Ferrari Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients J Urol 141 1989 1084
22. T.A. Stamey J.N. Kabalin J.E. McNeal Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients J Urol 141 1989 1076
23. A. Stein J.B. DeKernion R.B. Smith Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer J Urol 147 1992 942
24. J.G. Trapasso J.B. DeKernion R.B. Smith F. Dorey The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy J Urol 152 1994 1821
25. P.A. Wingo T. Tong S. Bolden Cancer statistics, 1995 CA Cancer J Clin 45 1995 8
26. G.K. Zagars Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy J Urol 152 1994 1786
27. G.K. Zagars A. Pollack V.S. Kavadi Von Eschenbach A. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 32 1995 293
28. A.L. Zietman J.J. Coen K.C. Dallow W.U. Shipley The treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcome Int J Radiat Oncol Biol Phys 32 1995 287
29. A.L. Zietman J.J. Coen W.U. Shipley Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome J Urol 151 1994 640
30. A.L. Zietman W.U. Shipley J.J. Coen Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: New insights into outcome from repeat biopsy and prostate-specific antigen followup J Urol 152 1994 1806
31. H. Zincke J.E. Oesterling M.L. Blute Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer J Urol 152 1994 1850